share_log

JPMorgan | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-JPMORGAN CHASE & CO.(4.0%)

JPMorgan | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

摩根大通 | SC 13G/A：超過5%持股股東披露文件(修正)
SEC announcement ·  04/10 01:20
牛牛AI助理已提取核心訊息
JPMorgan Chase & Co. has filed an amended Schedule 13G with the United States Securities and Exchange Commission on April 9, 2024, indicating a change in their holdings of Evolent Health, Inc. As of March 29, 2024, JPMorgan reported beneficial ownership of 4,679,353 shares of Evolent Health's Class A Common Stock, which represents 4.0% of the class. The filing shows that JPMorgan has sole voting power over 4,111,488 shares and shared voting power over 3,079 shares. Additionally, they have sole dispositive power over 4,664,522 shares and shared dispositive power over 3,131 shares. The filing indicates that JPMorgan has ceased to be the beneficial owner of more than five percent of Evolent Health's securities and that the shares were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of the issuer.
JPMorgan Chase & Co. has filed an amended Schedule 13G with the United States Securities and Exchange Commission on April 9, 2024, indicating a change in their holdings of Evolent Health, Inc. As of March 29, 2024, JPMorgan reported beneficial ownership of 4,679,353 shares of Evolent Health's Class A Common Stock, which represents 4.0% of the class. The filing shows that JPMorgan has sole voting power over 4,111,488 shares and shared voting power over 3,079 shares. Additionally, they have sole dispositive power over 4,664,522 shares and shared dispositive power over 3,131 shares. The filing indicates that JPMorgan has ceased to be the beneficial owner of more than five percent of Evolent Health's securities and that the shares were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of the issuer.
摩根大通已於2024年4月9日向美國證券交易委員會提交了經修訂的附表13G，表明其持有的Evolent Health, Inc.發生了變化。截至2024年3月29日，摩根大通報告了Evolent Health A類普通股的4,679,353股實益所有權，佔該類別的4.0％。該文件顯示，摩根大通擁有對4,111,488股股票的唯一投票權，對3,079股股票擁有共同投票權。此外，他們對4,664,522股股票擁有唯一的處置權，對3,131股股票擁有共同的處置權。該文件顯示，摩根大通已不再是Evolent Health超過5％的證券的受益所有人，這些股票是在正常業務過程中收購的，其目的不是改變或影響發行人的控制權。
摩根大通已於2024年4月9日向美國證券交易委員會提交了經修訂的附表13G，表明其持有的Evolent Health, Inc.發生了變化。截至2024年3月29日，摩根大通報告了Evolent Health A類普通股的4,679,353股實益所有權，佔該類別的4.0％。該文件顯示，摩根大通擁有對4,111,488股股票的唯一投票權，對3,079股股票擁有共同投票權。此外，他們對4,664,522股股票擁有唯一的處置權，對3,131股股票擁有共同的處置權。該文件顯示，摩根大通已不再是Evolent Health超過5％的證券的受益所有人，這些股票是在正常業務過程中收購的，其目的不是改變或影響發行人的控制權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。